SCHEMBL2184285

SCHEMBL2184285

CN1CCN(CCCOc2cc(C(=NO)Nc3ccc(F)c(Cl)c3)on2)CC1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.52
EGFR P00533 4/20 0.46
ERBB2 P04626 1/20 0.46
KDR P35968 1/20 0.45
CSF1R P07333 2/20 0.44
MCHR1 Q99705 13/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2184275 1.00 RAB9A (0.52) RAB9AEGFRERBB2KDRCSF1R
SCHEMBL2184076 0.93 HRH3 (0.46) RAB9AEGFRKDR
SCHEMBL2184070 0.93 HRH3 (0.46) RAB9AEGFRKDR
SCHEMBL12415213 0.91 EPHX2 (0.51) EGFRERBB2KDR
SCHEMBL12507281 0.88 RAB9A (0.52) RAB9AEGFRERBB2KDRCSF1R
SCHEMBL2184300 0.83 IDO1 (0.44) RAB9A
SCHEMBL14077055 0.83 MEN1 (0.43)
SCHEMBL12506969 0.81 HRH3 (0.47) RAB9AEGFRKDR
SCHEMBL2184331 0.81 MEN1 (0.54) EGFR
SCHEMBL12506965 0.79 EPHX2 (0.52) EGFRERBB2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064194-B1 N-HYDROXYAMIDINOHETEROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE HOLDINGS CORP (US) 2018-11-07 EP claimed
US-8507541-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-08-13 US claimed
US-20110165188-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation a Delaware corporation 2011-07-07 US claimed
US-20080214546-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-09-04 US claimed
EP-2064194-B1 N-HYDROXYAMIDINOHETEROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE HOLDINGS CORP (US) 2018-11-07 EP disclosed
US-8507541-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-08-13 US disclosed
US-8507541-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-08-13 US disclosed
US-20110165188-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation a Delaware corporation 2011-07-07 US disclosed
US-20110165188-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation a Delaware corporation 2011-07-07 US disclosed
US-20080214546-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-09-04 US disclosed
US-20080214546-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214546-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT RAB9A 3376/4885EGFR 2945/4885ERBB2 1558/4885
US-20110165188-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT RAB9A 3376/4885EGFR 2945/4885ERBB2 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.